Opinion and uptake of chloroquine for treatment of COVID-19 during the mandatory lockdown in the sub-Saharan African region.
Adolescent
Adult
Africa South of the Sahara
Chloroquine
/ therapeutic use
Communicable Disease Control
Female
Health Knowledge, Attitudes, Practice
Humans
Hydroxychloroquine
/ therapeutic use
Male
Middle Aged
Pandemics
/ prevention & control
Public Opinion
SARS-CoV-2
Surveys and Questionnaires
Young Adult
COVID-19 Drug Treatment
Africa
chloroquine hydrochloride
coronavirus
poisoning
sub-Saharan Africa
Journal
African journal of primary health care & family medicine
ISSN: 2071-2936
Titre abrégé: Afr J Prim Health Care Fam Med
Pays: South Africa
ID NLM: 101520860
Informations de publication
Date de publication:
15 Jun 2021
15 Jun 2021
Historique:
received:
12
10
2020
accepted:
04
03
2021
revised:
25
02
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
8
7
2021
Statut:
epublish
Résumé
As the search for effective treatment of coronavirus disease 2019 (COVID-19) infection continues, the public opinion around the potential use of chloroquine (CQ) in treating COVID-19 remains mixed. To examine opinion and uptake of CQ for treating COVID-19 in the sub-Saharan African (SSA) region. This study was conducted through an online survey software titled SurveyMonkey. Anonymous online survey of 1829 SSA countries was conducted during the lockdown period using Facebook, WhatsApp and authors' networks. Opinion and uptake of CQ for COVID-19 treatment were assessed using multivariate analyses. About 14% of respondents believed that CQ could treat COVID-19 and of which, 3.2% took CQ for COVID-19 treatment. Multivariate analyses revealed that respondents from Central (adjusted odds ratios [aOR]: 2.54, 95% confidence interval [CI] 1.43, 4.43) and West Africa (aOR: 1.79, 95% CI 1.15, 2.88) had higher odds of believing that CQ could treat COVID-19. Respondents from East Africa reported higher odds for uptake of CQ for COVID-19 than Central, Western and Southern Africans. Knowledge of the disease and compliance with the public health advice were associated with both belief and uptake of CQ for COVID-19 treatment. Central and West African respondents were more likely to believe in CQ as a treatment for COVID-19 whilst the uptake of the medication during the pandemic was higher amongst East Africans. Future intervention discouraging the unsupervised use of CQ should target respondents from Central, West and East African regions.
Sections du résumé
BACKGROUND
BACKGROUND
As the search for effective treatment of coronavirus disease 2019 (COVID-19) infection continues, the public opinion around the potential use of chloroquine (CQ) in treating COVID-19 remains mixed.
AIM
OBJECTIVE
To examine opinion and uptake of CQ for treating COVID-19 in the sub-Saharan African (SSA) region.
SETTING
METHODS
This study was conducted through an online survey software titled SurveyMonkey.
METHODS
METHODS
Anonymous online survey of 1829 SSA countries was conducted during the lockdown period using Facebook, WhatsApp and authors' networks. Opinion and uptake of CQ for COVID-19 treatment were assessed using multivariate analyses.
RESULTS
RESULTS
About 14% of respondents believed that CQ could treat COVID-19 and of which, 3.2% took CQ for COVID-19 treatment. Multivariate analyses revealed that respondents from Central (adjusted odds ratios [aOR]: 2.54, 95% confidence interval [CI] 1.43, 4.43) and West Africa (aOR: 1.79, 95% CI 1.15, 2.88) had higher odds of believing that CQ could treat COVID-19. Respondents from East Africa reported higher odds for uptake of CQ for COVID-19 than Central, Western and Southern Africans. Knowledge of the disease and compliance with the public health advice were associated with both belief and uptake of CQ for COVID-19 treatment.
CONCLUSION
CONCLUSIONS
Central and West African respondents were more likely to believe in CQ as a treatment for COVID-19 whilst the uptake of the medication during the pandemic was higher amongst East Africans. Future intervention discouraging the unsupervised use of CQ should target respondents from Central, West and East African regions.
Identifiants
pubmed: 34212739
doi: 10.4102/phcfm.v13i1.2795
pmc: PMC8252178
doi:
Substances chimiques
Hydroxychloroquine
4QWG6N8QKH
Chloroquine
886U3H6UFF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1-e8Références
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
Eye (Lond). 2020 Aug;34(8):1301-1302
pubmed: 32055019
JAMA. 2020 Jun 23;323(24):2493-2502
pubmed: 32392282
J Mol Cell Biol. 2020 May 18;12(4):322-325
pubmed: 32236562
Health Commun. 2015;30(6):566-76
pubmed: 25010519
J Crit Care. 2020 Jun;57:279-283
pubmed: 32173110
BMJ. 2020 Apr 8;369:m1432
pubmed: 32269046
Health Policy Plan. 1999 Jun;14(2):89-102
pubmed: 10538724
Br J Clin Pharmacol. 1983 Apr;15(4):502-3
pubmed: 6849790
Int J Environ Res Public Health. 2020 Jul 21;17(14):
pubmed: 32708161
Res Social Adm Pharm. 2021 Jan;17(1):1954-1963
pubmed: 32387230
Am J Trop Med Hyg. 2020 Jun;102(6):1184-1188
pubmed: 32323646
Ann Trop Med Parasitol. 2011 Sep;105(6):447-53
pubmed: 22117854
Travel Med Infect Dis. 2020 Jul - Aug;36:101791
pubmed: 32593867
Nat Rev Drug Discov. 2020 May;19(5):305-306
pubmed: 32273591
JAMA. 2021 Jan 26;325(4):327-328
pubmed: 33404589
Trop Med Int Health. 2003 Feb;8(2):133-9
pubmed: 12581438
Clin Infect Dis. 2020 Jul 28;71(15):888-889
pubmed: 32211771
PLoS One. 2014 Feb 20;9(2):e89177
pubmed: 24586574
Malar J. 2016 Jul 02;15(1):339
pubmed: 27368160
Appl Microbiol Biotechnol. 2021 Feb;105(4):1333-1343
pubmed: 33515285
Psychol Med. 2020 May 21;:1-13
pubmed: 32436485
Trop Med Int Health. 2003 Aug;8(8):685-92
pubmed: 12869089
Res Rep Trop Med. 2020 Sep 17;11:61-72
pubmed: 32982538
Int J Antimicrob Agents. 2020 Mar;55(3):105923
pubmed: 32070753
Malar J. 2018 Nov 14;17(1):424
pubmed: 30428880
Int J Infect Dis. 2020 Jun;95:192-197
pubmed: 32305520
Int J Antimicrob Agents. 2020 May;55(5):105955
pubmed: 32234468
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Malar J. 2020 Feb 18;19(1):76
pubmed: 32070358